Table 2.
Serologic and clinical findings in infants with congenital toxoplasmosis born to treated and untreated mothers in the United States.
| No. of infants aged 0–180 days*
|
p value | (95% CI) | |||
|---|---|---|---|---|---|
| Treated (n = 25) | Untreated (n = 164) | ||||
| Serologic findings | IgM(+)/IgM performed (%) | 11/25 (44) | 142/164 (86.6) | <0.001 | (0.04–0.3) |
| IgA(+)/IgA performed (%) | 15/25 (60) | 127/164 (77.4) | 0.06 | (0.18–1.05) | |
| IgE(+)/IgE performed (%) | 3/16 (18.7) | 41/102 (40.2) | 0.1 | (0.09–1.28) | |
| Eye disease/n (%) | 10/16 (62.5) | 119/129 (92.2) | 0.003 | (0.04–0.46) | |
| Clinical findings | Cerebral calcifications/n (%) | 13/17 (76.5) | 94/118 (79.7) | 0.75 | (0.24–2.77) |
| Hydrocephalus/n (%) | 5/13 (38.5) | 67/99 (67.7) | 0.039 | (0.09–0.98) | |
| E + C + H/n (%) | 3/11 (27.3) | 53/86 (61.6) | 0.048 | (0.05–0.94) | |
*
Age when first serum was drawn for testing.
E: eye disease, C: calcifications, H: hydrocephalus, n: number of evaluated infants, CI: confidence interval for odds-based parameters.